During the Elan price collapse in February 2005, the internet investment boards were buzzing with an unusual angle to the story. Investors were talking about a buying opportunity after the suspension of multiple scelerosis drug Tysabri, and were pointing to Elan’s leading role in nanotechnology for their enthusiasm.
Since then, the global buzz about nanotechnology has not abated and Elan has a world-leading position in the industry. Nanotechnology in the pharmaceutical industry is about...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team